ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
61,781.04
-0.05%
S&P 500
5,465.36
-0.07%
Dow Jones
38,998.22
-0.29%
US Dollar vs Yen
160.5705
0.55%
Brent Oil
83.81
-0.45%
Registration Strip Icon for monitor ブラジル証券取引所、NASDAQ、NYSE、AMEX、LSEなどの主要取引所からの複数のリアルタイム株価を監視します。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ
  6. Vir Biotechnology Inc (VIR)

  7. Vir Biotechnology Inc (VIR) ニュース

VIR

Vir Biotechnology (VIR)

Vir Biotechnology Inc
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:VIR
日付受信時刻ニュースソース見出しコード企業名
2024/06/2621 : 05Business WireVir Biotechnology Receives FDA IND Clearance and Fast Track Designation for Tobevibart and Elebsiran for the Treatment of Chronic Hepatitis Delta InfectionNASDAQ:VIRVir Biotechnology Inc
2024/06/1305 : 00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VIRVir Biotechnology Inc
2024/06/0519 : 04Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VIRVir Biotechnology Inc
2024/06/0518 : 30Business WireTobevibart Monotherapy and Combination Therapy with Elebsiran Achieved High Virologic Response and ALT Normalization in People Living with the Hepatitis Delta Virus After 12 and 24 Weeks of TreatmentNASDAQ:VIRVir Biotechnology Inc
2024/06/0401 : 13Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VIRVir Biotechnology Inc
2024/06/0400 : 57Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:VIRVir Biotechnology Inc
2024/06/0103 : 43Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VIRVir Biotechnology Inc
2024/06/0103 : 42Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:VIRVir Biotechnology Inc
2024/05/3005 : 06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VIRVir Biotechnology Inc
2024/05/3005 : 05Business WireVir Biotechnology to Participate in the Goldman Sachs 45th Annual Global Healthcare ConferenceNASDAQ:VIRVir Biotechnology Inc
2024/05/2921 : 05Business WireVir Biotechnology Appoints Mark Eisner, M.D., M.P.H. as Chief Medical OfficerNASDAQ:VIRVir Biotechnology Inc
2024/05/2405 : 05Business WireVir Biotechnology to Host 2024 Annual Meeting of StockholdersNASDAQ:VIRVir Biotechnology Inc
2024/05/2221 : 05Business WireMultiple Abstracts Highlighting Vir Biotechnology’s Latest Hepatitis Delta & B Data Accepted for Presentation at the EASL Congress 2024NASDAQ:VIRVir Biotechnology Inc
2024/05/2121 : 17Business WireVir Biotechnology Announces SOLSTICE Data to be Featured as an Oral Presentation at the European Association for the Study of the Liver (EASL) Congress 2024NASDAQ:VIRVir Biotechnology Inc
2024/05/1505 : 05Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:VIRVir Biotechnology Inc
2024/05/0305 : 05Business WireVir Biotechnology Provides Corporate Update and Reports First Quarter 2024 Financial ResultsNASDAQ:VIRVir Biotechnology Inc
2024/05/0105 : 05Business WireVir Biotechnology to Participate in the BofA Securities Healthcare Conference 2024NASDAQ:VIRVir Biotechnology Inc
2024/04/1821 : 00Business WireVir Biotechnology Announces Nomination of Norbert Bischofberger, Ph.D. and Ramy Farid, Ph.D. to its Board of DirectorsNASDAQ:VIRVir Biotechnology Inc
2024/04/1205 : 30Business WireVir Biotechnology to Provide Business Update and Report First Quarter 2024 Financial Results on May 2, 2024NASDAQ:VIRVir Biotechnology Inc
2024/03/0522 : 05Business WireVir Biotechnology Completes Enrollment of Phase 2 Chronic Hepatitis Delta SOLSTICE Trial Ahead of ScheduleNASDAQ:VIRVir Biotechnology Inc
2024/02/2709 : 34Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VIRVir Biotechnology Inc
2024/02/2709 : 32Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VIRVir Biotechnology Inc
2024/02/2709 : 32Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VIRVir Biotechnology Inc
2024/02/2709 : 31Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VIRVir Biotechnology Inc
2024/02/2706 : 27Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:VIRVir Biotechnology Inc
2024/02/2706 : 10Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:VIRVir Biotechnology Inc
2024/02/2322 : 05Business WireVir Biotechnology to Participate in Upcoming Investor Healthcare ConferencesNASDAQ:VIRVir Biotechnology Inc
2024/02/2306 : 12Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VIRVir Biotechnology Inc
2024/02/2306 : 05Business WireVir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:VIRVir Biotechnology Inc
2024/02/2106 : 33Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VIRVir Biotechnology Inc
 Showing the most relevant articles for your search:NASDAQ:VIR

最近閲覧した銘柄

USOTC
DTEGY
Deutsche Telekom (QX)
CCOM
US500
US 500
NYSE
XOM
Exxon Mobil
NYSE
NKE
Nike
NYSE
JPM
JP Morgan Chase
COIN
SOLUSD
Solana
CCOM
SILVER
SILVER
SPI
SP500
S&P 500
CCOM
US30
US 30
NYSE
CVX
Chevron
NYSE
BAC
Bank of America
USOTC
BASFY
BASF (QX)
COIN
ETHUSD
Ethereum
USOTC
ADDYY
Adidas (QX)
NYSE
DIS
Walt Disney
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

日本
会社情報
ビジネス
人気
アプリを入手
App Store
Google Play

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2024 ADVFN PLC - 全著作権所有